ClinicalTrials.gg
Not yet recruitingNCT07857486DECREASEUpdated Oct 5, 2026

Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer

A Phase 2 interventional study of Pembrolizumab in Early Triple-Negative Breast Cancer, sponsored by Institut Paoli-Calmettes. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Institut Paoli-Calmettes · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms — 17 open to participants now, 27 under way, 4 of them phase 3. pembrolizumab · Triple Negative Breast Neoplasms.

Planned enrollment
17th of 49
84 · median 52
Started
2026
with 3 others
Phase 2
33 of 49
13 open now
Primary completion
2029-02
later than 19 of 26 live
Registered
48th of 49
by date

Among the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, this one is the 17th largest by planned enrollment, is one of 4 that started in 2026, is one of 33 in phase 2, reaches primary completion later than 19 of the 26 other live ones, and was the 48th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

17 of the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This multicenter phase II study evaluates a de-escalation strategy of neoadjuvant chemo-immunotherapy in patients with stage II early triple-negative breast cancer and tumor-infiltrating lymphocytes (TILs) ≥ 30%. Patients will receive 12 weeks of neoadjuvant treatment with carboplatin, paclitaxel, and pembrolizumab.

The primary objective is to assess the efficacy of this treatment strategy by evaluating the proportion of patients with no suspected residual tumor on breast MRI and biopsy after 12 weeks of neoadjuvant therapy, confirmed by pathological examination of the surgerey sample.

Read the detailed description

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. The KEYNOTE-522 trial established neoadjuvant chemotherapy combined with pembrolizumab as a standard treatment for patients with stage II-III TNBC, resulting in improved pathological complete response rates and survival outcomes. However, this treatment approach is associated with substantial toxicity, which may lead to treatment discontinuation and long-term adverse effects.

Patients who achieve a pathological complete response have an excellent prognosis, supporting the development of treatment de-escalation strategies. High levels of tumor-infiltrating lymphocytes (TILs) are associated with increased response rates and favorable outcomes in TNBC.

This multicenter, prospective, phase II, non-comparative study aims to evaluate a de-escalated neoadjuvant treatment strategy in patients with stage II TNBC and TILs ≥30%. Participants will receive 12 weeks of neoadjuvant treatment with carboplatin, paclitaxel, and pembrolizumab.

The primary objective is to evaluate the proportion of patients with no suspected residual tumor on breast MRI and biopsy after 12 weeks of treatment, confirmed by pathological examination at surgery. Secondary objectives include evaluation of event-free survival, overall survival, residual cancer burden, safety, quality of life, fear of cancer recurrence, and the association between imaging findings, TIL levels, and treatment response. Exploratory analyses will investigate potential circulating and tissue biomarkers associated with treatment efficacy.

03

Conditions studied

  • Early Triple-Negative Breast Cancer

Keywords

  • Triple-Negative Breast Cancer Stage II
  • Neoadjuvant Therapy
  • Chemo-Immunotherapy
  • Treatment De-escalation
  • Pembrolizumab /Carboplatin /Paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18 years or older.
  2. Signed for study participation.
  3. and/or cytologically confirmed invasive triple-negative breast adenocarcinoma (ER and PR \< 10%, -negative), documented on all tumor samples.
  4. Stage II disease: T2-T3N0M0 or T1-T2N1M0.
  5. Tumor-infiltrating lymphocytes (TILs) ≥ 30% on the initial (TILs will be assessed according to the recommendations of the International TILs Working Group 2014).
  6. Availability of tumor tissue samples.
  7. Performance Status ≤ 1.
  8. No to chemotherapy or pembrolizumab.
  9. Adequate bone marrow function, defined as follows (laboratory assessments performed within 21 days prior to enrollment):

    ≥ 1,500/μL (1.5 × 10⁹/L) ≥ 10 g/dL count ≥ 100,000/μL (100 × 10⁹/L)

  10. Adequate hepatic function, defined as follows (laboratory assessments performed within 21 days prior to enrollment):

    Total serum ≤ 1.5 × ; for subjects with known Gilbert's syndrome, ≤ 3 × ULN is permitted (SGOT) ≤ 2.0 × ULN ALT (SGPT) ≤ 2.0 × ULN Alkaline phosphatase (ALP) ≤ 2.5 × ULN

  11. Adequate renal function, defined as follows (laboratory assessments performed within 21 days prior to enrollment):

    Serum creatinine ≤ 1.5 × ULN or estimated (eGFR) ≥ 40 mL/min/1.73 m²

  12. (LVEF) ≥ 50%, assessed by echocardiography. A routine LVEF assessment is acceptable if performed within 28 days prior to the start of screening.
  13. Adequate serum potassium, magnesium, and calcium levels (> ULN).
  14. Negative serum pregnancy test at screening for subjects of .
  15. Women of childbearing potential must agree to use a highly effective method of during the screening period, throughout study treatment, and for at least 7 months after the last administration of study treatment. It is strongly recommended that the male partner of a female participant also use a male condom with spermicide throughout this period.
  16. Affiliation with, or beneficiary of, a health insurance system.
  17. Ability to communicate and understand French without difficulty.

Exclusion criteria

Exclusion Criteria:

  1. disease at diagnosis.
  2. Relapse of a previous breast cancer.
  3. Bilateral breast cancer.
  4. Invasive breast adenocarcinoma with ER and PR > 10% and/or -positive disease.
  5. Any other within the previous 3 years, except for cancers considered adequately treated and at low risk of recurrence.
  6. Pregnant or breastfeeding women, or women likely to become pregnant due to lack of effective .
  7. to MRI.
  8. Diagnosis of immunodeficiency.
  9. Active disease (e.g., inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, multiple sclerosis, celiac disease, Wegener's granulomatosis) requiring systemic treatment within the previous 3 years (i.e., disease-modifying agents, , or drugs).
  10. Prior treatment with systemic immunosuppressive medications (except physiologic replacement corticosteroids) within 30 days before the planned start of study treatment.
  11. Receipt of a live (attenuated) vaccine within 30 days before the planned start of study treatment.
  12. Active infection, including:

    Tuberculosis (TB); (known positive hepatitis B surface antigen [HBsAg]). Subjects with past or resolved HBV infection (defined by positive anti-HBc antibodies and negative HBsAg) are eligible; . Subjects positive for anti-HCV antibodies are eligible only if HCV RNA is negative by polymerase chain reaction (PCR); (HIV) infection. HIV-positive subjects are eligible if receiving treatment and having an undetectable viral load.

  13. Significant cardiovascular disease, including (NYHA) Class II or higher heart disease, cardiomyopathy, acute inflammatory heart disease, myocardial infarction, (TIA), stroke within the previous 3 months, unstable arrhythmias, and/or unstable angina.
  14. Participation in another study involving one or more medicinal products within 3 weeks before study entry (or within a period equivalent to 5 half-lives before the first dose of the study intervention). Participation in observational studies or long-term follow-up of other studies is permitted provided that no procedures likely to interfere with the interpretation of the present study results are performed.
  15. Prior systemic therapy or curative radiotherapy for the current breast cancer.
  16. Ongoing acute urinary tract infection, pre-existing hemorrhagic cystitis, or known urinary tract obstruction.
  17. Known or suspected , or severe allergy, to any active substance or of the study drugs, including lactose.
  18. Any uncontrolled medical condition, neuropsychiatric disorder, or significant substance dependence that, in the opinion of the Principal Investigator, could interfere with study completion.
  19. Vulnerable persons as defined under Article L.1121-6 of the French Public Health Code, adults under legal protection measures, or individuals unable to provide in accordance with Article L.1121-8 of the French Public Health Code.
  20. Current use of St. John's Wort (Hypericum perforatum).
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    De-escalated Neoadjuvant Chemo-Immunotherapy

    Participants receive neoadjuvant treatment with carboplatin, paclitaxel, and pembrolizumab for 12 weeks as part of a treatment de-escalation strategy for stage II early triple-negative breast cancer with tumor-infiltrating lymphocytes (TILs) ≥30%.

    Drug: Pembrolizumab

Interventions

  • Pembrolizumab administered in combination with carboplatin and paclitaxel as neoadjuvant treatment ( 12 weeks) for stage II early triple-negative breast cancer.

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Without Residual Tumor After 12 Weeks of Neoadjuvant Treatment

    Proportion of patients with no suspected residual tumor on breast MRI and biopsy after 12 weeks of neoadjuvant treatment, confirmed by pathological examination at surgery.

    Time frame: 12 weeks

Secondary outcomes

  1. Event-Free Survival (EFS)

    Event-free survival.

    Time frame: 3 years

  2. Overall Survival (OS)

    Overall survival.

    Time frame: 3 years

  3. Residual Cancer Burden (RCB)

    Residual Cancer Burden (RCB) will be calculated as a continuous index combining pathological measurements of the primary tumor (size and cellularity) and nodal metastases (number and size), according to the method described by Symmans et al. RCB-0 is defined as pathological complete response (pCR; ypT0/Tis ypN0). RCB-1 corresponds to minimal residual disease, RCB-2 to moderate residual disease, and RCB-3 to extensive residual disease.

    Time frame: At surgery

  4. Treatment-Related Toxicity

    Toxicity related to chemotherapy and immunotherapy will be assessed according to the occurrence and severity of adverse events of interest associated with chemotherapy and pembrolizumab treatment.Incidence of Adverse Events

    Time frame: Up to 51 weeks

  5. Quality of Life will be assessed

    Quality of life will be assessed using the EORTC QLQ-C30 questionnaire at baseline, before surgery, and 3 months after surgery,

    Time frame: From baseline up to 3 years

  6. Fear of Cancer Recurrence

    Fear of cancer recurrence will be assessed using the French version of the Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF), a 9-item questionnaire, at baseline, before surgery, and at each post-treatment follow-up visit over a 3-year period.

    Time frame: From baseline up to 3 years

  7. Correlation Between Complete Response on Breast Magnetic Resonance Imaging and Residual Cancer Burden 0 (RCB-0)

    Complete response assessed by breast magnetic resonance imaging (MRI) will be compared with pathological complete response assessed by Residual Cancer Burden (RCB) classification. Pathological complete response is defined as RCB-0. The proportion (%) of patients with MRI complete response among patients classified as RCB-0 at surgery will be evaluated..

    Time frame: At surgery

  8. Association Between Baseline TILs and Residual Cancer Burden

    Pre-treatment tumor-infiltrating lymphocyte (TIL) levels, analyzed as both continuous and dichotomous variables, will be compared across RCB-0, RCB-1, and RCB-2/3 categories.

    Time frame: Baseline and at surgery

  9. Quality of life assessed by EQ-5D-5L

    EQ-5D-5L questionnaire at each follow-up visit over a 3-year period.the EQ-5D-5L descriptive system consists of five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with five response levels. Responses are converted into a single index value, with scores typically ranging from less than 0 (health states worse than death) to 1.0 (full health). Higher scores indicate better health-related quality of life.

    Time frame: From baseline up to 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2029, 27 months later.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 27 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Oct 5, 2026
StartEst.
Nov 2026
Primary completionEst.
Feb 2029
CompletionEst.
Nov 2032
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857486
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Nov 2026 (estimated)
Primary completion
Feb 2029 (estimated)
Completion
Nov 2032 (estimated)
Last update
Oct 5, 2026

Study contacts

Jihane PAKRADOUNI, Director of the Department of
Contact
pakradounij@ipc.unicancer.fr
+33 4 91 22 37 78
SONIA AMOKRANE, Clinical Project Manager
Contact
amokranes@ipc.unicancer.fr
+33 4 91 22 37 82
LORENE SEGUIN, MD
principal investigator · Paoli-Calmettes Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion